Guardant Health (GH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.42
- Estimate
- -$0.39
- Surprise
- -7.8%
- Revenue (period 2026-06-30)
- $335.0M
- Score at report (before → after)
- 5.3 → 5.6/10
Revenue source: xbrl.
How the report landed
Guardant Health (GH) reported a wider loss than forecast — adjusted EPS of -$0.42 against the -$0.39 estimate (a 7.8% shortfall). TrendMatrix's engine moved from Data Issue (5.3/10) to Hold at 5.6/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GH Hold at 5.7/10.
2 of the last 4 quarters beat the estimate; this quarter's -7.8% surprise compares with a +2.7% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+1.00)
What argues against it
- Concentration risk — Product: tests (94.0%)
- Thin upside margin: 4.7%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $173.25
- Price target
- $181.48
- Stop
- $161.12
- Upside to target
- +4.8%
- Reward-to-risk
- 0.5:1
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
GH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $23.25B
- P/E (fwd)
- -456.9
- 52-week range
- $68.02–$191.05
- Off 52-week high
- 9.3%
- RSI (14)
- 53
- Volume vs avg
- 1.11×
- Score today
- 5.7/10